| Objective: To explore the clinical efficacy and application of guizhi fuling capsule combined with mifepristone in the treatment of uterine fibroids. Methods: 80 Patients with uterine fibroids treated in our hospital from August 2018 to August 2019 were selected as the research subjects. According to the principle of random grouping, the patients were divided into two groups, namely the control group and the study group. Patients in the control group were treated with a single mifepristone, and the study group was treated with guizhi fuling capsules in combination. After treatment, the uterine volume, fibroid volume, and serum sex hormone levels of the two groups of patients were compared, and the incidence of related adverse reactions was calculated to evaluate the treatment effects of the two regimens. Results: After treatment, the uterine volume and fibroid volume of the study group were significantly smaller than those of the control group, and the serum sex hormone levels were better than those of the control group, and the differences were statistically significant (P＜0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups of patients, P＞0.05. Among them, the uterine volume and fibroid volume of patients in the study group were (105.34±26.32)cm3 and (35.02±15.14)cm3, while those in the control group were (115.67±26.49)cm3 and (46.13±15.64)cm3. The difference was statistically significant. Meaningful, P＜0.05. Conclusion: Guizhi fuling capsule combined with mifepristone has a significant effect on patients with uterine fibroids. It can effectively reduce the volume of uterine and fibroids and improve the serum sex hormone levels. It has high clinical application value. |
